COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,864 Articles (22,568 medRxiv, 8,296 bioRxiv)

Most recent first Previous |  Page 1896: Articles 18951-18960  | Next

Smoking and SARS-CoV-2 Impair Dendritic Cells and Regulate DC-SIGN Expression in Tissues
Cai, G., Bosse, Y., Du, M., Albrecht, H., Qin, F., Yu, X., Luo, X., Androulakis, M., Zhu, X., Zhou, J., Cui, X., Yi, C., Cheng, C., Nagarkatti, M., Nagarkatti, P., Christiani, D., Whitfield, M., Amos, C., Xiao, F.
10.1101/2020.12.23.20245316 — Posted: 2020-12-30
S gene dropout patterns in SARS-CoV-2 tests suggest spread of the H69del/V70del mutation in the US.
Washington, N. L., White, S., Schiabor Barrett, K. m., Cirulli, E. T., Bolze, A., Lu, J. T.
10.1101/2020.12.24.20248814 — Posted: 2020-12-30
Simulating Retarded SEIRS model for COVID-19: will the second epidemic happen?
Pour Mohammad, H.
10.1101/2020.12.24.20248842 — Posted: 2020-12-30
Unraveling COVID-19-related hospital costs: The impact of clinical and demographic conditions
Anna Miethke-Morais, A., Cassenote, A., Piva, H., Tokunaga, E., Cobello, V., Alves, F. A. R., Lobo, R. A. d. S., Trindade, E., Carneiro D'Albuquerque, L. A., HCFMUSP Covid-19 Study Group, , Haddad, L.
10.1101/2020.12.24.20248633 — Posted: 2020-12-30
Development of a Multivariable Model for COVID-19 Risk Stratification Based on Gradient Boosting Decision Trees
Gutierrez, J. M., Volkovs, M., Poutanen, T., Watson, T., Rosella, L.
10.1101/2020.12.23.20248783 — Posted: 2020-12-30
Process Development and Scale-up Optimization of the SARS-CoV-2 Receptor Binding Domain-Based Vaccine Candidate, RBD219-N1C1
Lee, J., Liu, Z., Chen, W.-H., Wei, J., Kundu, R., Adhikari, R., Altieri Rivera, J., Gillespie, P. M., Strych, U., Zhan, B., Hotez, P. J., Bottazzi, M. E.
10.1101/2020.12.30.424829 — Posted: 2020-12-30
Characterization of cell-cell communication in COVID-19 patients
Lin, Y., Loo, L., Tran, A., Moreno, C., Hesselson, D., Neely, G. G., Yang, J. Y. H.
10.1101/2020.12.30.424641 — Posted: 2020-12-30
Screening a library of FDA-approved and bioactive compounds for antiviral activity against SARS-CoV-2
Biering, S. B., Van Dis, E., Wehri, E., Yamashiro, L. H., Nguyenla, X., Dugast-Darzacq, C., Graham, T. G., Stroumza, J. R., Golovkine, G. R., Roberts, A. W., Fines, D. M., Spradlin, J. N., Ward, C. C., Bajaj, T., Dovala, D., Gahmen, U. S., Bajaj, R., Fox, D. M., Ott, M., Murthy, N., Nomura, D., Schaletzky, J., Stanley, S. A.
10.1101/2020.12.30.424862 — Posted: 2020-12-30
A novel fermented Yi traditional medicine efficiently suppresses the replication of SARS-CoV-2 in vitro
Fang, S., Xu, B., Song, X., Xie, Y., Yang, X.
10.1101/2020.12.29.424534 — Posted: 2020-12-30
Engineering, production and characterization of Spike and Nucleocapsid structural proteins of SARS-CoV-2 in Nicotiana benthamiana as vaccine candidates against COVID-19
Mammedov, T., Yuksel, D., Ilgin, M., Gurbuzaslan, I., Gulec, B., Mammadova, G., Say, D., Hasanova, G.
10.1101/2020.12.29.424779 — Posted: 2020-12-30

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).